文献速递脊柱关节炎

古塞奇尤单抗治疗TNFi-IR银屑病关节炎:指炎和附着点炎缓解对疾病控制的影响

Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

COSMOS试验事后分析纳入285例TNFi-IR活动性PsA患者,随机接受古塞奇尤单抗100mg或安慰剂。古塞奇尤单抗组W24指炎/附着点炎缓解率分别为44.8%/39.7%,高于安慰剂组的25.0%/18.8%,至W48升至67.2%/55.6%。W24缓解与W48严格疾病控制指标达成相关。

要点

  • 基线时36.1%患者有指炎,66.7%有附着点炎。
  • 古塞奇尤单抗组W24指炎缓解44.8%、附着点炎缓解39.7%,均高于安慰剂组。
  • W24指炎/附着点炎缓解与W48多项严格疾病控制指标达成相关。

核心结论

  • 古塞奇尤单抗治疗使TNFi-IR银屑病关节炎患者至W48维持较高的指炎和附着点炎缓解率。
  • W24指炎或附着点炎缓解与W48疾病控制达标相关,为基于W24治疗反应进行临床决策提供参考。

研究设计与样本

  • COSMOS为IIIb期试验,285例TNFi-IR活动性银屑病关节炎成人按2:1随机接受古塞奇尤单抗100mg或安慰剂,W0、W4给药,此后每8周至W44。
  • 本分析为事后分析,采用逻辑回归评估W24指炎缓解或附着点炎缓解与W48严格疾病控制指标达成之间的关联。
  • 指炎采用指炎严重程度评分(DSS)评估,附着点炎采用利兹附着点炎指数(LEI)评估。

主要发现

  • 基线时103/285(36.1%)例患者有指炎(DSS≥1),190/285(66.7%)例有附着点炎(LEI≥1)。
  • 有指炎者较无指炎者更常合并附着点炎、更多关节受累(SJC/DAPSA)和皮肤受累、PGA评分更高、BMI更低。
  • 有附着点炎者较无附着点炎者更常为女性、合并指炎、更多关节受累(SJC/TJC/DAPSA)、身体功能更差(HAQ-DI/SF-36 PCS)。
  • 古塞奇尤单抗组较安慰剂组更多患者达到指炎缓解/附着点炎缓解(W24:44.8%/39.7% vs 25.0%/18.8%)。
  • 古塞奇尤单抗随机化患者中指炎/附着点炎缓解率至W48升高(67.2%/55.6%)。

关键数值与推荐

  • 指炎缓解定义为DSS=0,附着点炎缓解定义为LEI=0(根据DSS≥1和LEI≥1基线定义推断)。
  • W24指炎缓解与W48严格疾病控制指标相关的OR范围为3.28-13.38。
  • W24附着点炎缓解与W48严格疾病控制指标相关的OR范围为2.88-6.09。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR). METHODS: In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100 mg or placebo at Week (W)0, W4, then every 8 weeks until W44. The Dactylitis Severity Score (DSS) and Leeds Enthesitis Index (LEI) assessed dactylitis and enthesitis, respectively. This post hoc analysis evaluated associations between W24 DR or ER and W48 achievement of stringent disease control measures using logistic regression. RESULTS: At baseline, 103/285 (36.1%) patients had dactylitis (DSS ≥ 1) and 190/285 (66.7%) had enthesitis (LEI ≥ 1). Patients with dactylitis were more likely to have enthesitis, more joint (SJC/DAPSA) and skin involvement, higher PGA score and lower BMI vs those without dactylitis. Patients with enthesitis were more likely to be female, and have dactylitis, more joints affected (SJC/TJC/DAPSA) and worse physical functioning (HAQ-DI/SF-36 PCS) vs those without enthesitis. Greater proportions of guselkumab- vs placebo-treated patients achieved DR/ER (W24: 44.8%/39.7% vs 25.0%/18.8%); rates increased through W48 among guselkumab-randomized patients (67.2%/55.6%). W24 resolution was associated with W48 achievement of stringent measures, including ACR50/70, DAPSA LDA/remission, PASI100, PASDAS LDA/VLDA and MDA/VLDA (odds ratios: DR, 3.28-13.38; ER, 2.88-6.09). CONCLUSION: Guselkumab treatment resulted in high DR/ER rates through W48 in TNFi-IR PsA patients. W24 DR/ER was associated with W48 disease control, providing valuable insights for clinical decision-making based on W24 treatment responses.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Marzo-Ortega H, McInnes IB, Sharaf M, et al. Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis. Rheumatology (Oxford). 2026. PMID: 40971670. doi:10.1093/rheumatology/keaf490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。